FY2028 Earnings Forecast for BBIO Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2028 earnings estimates for BridgeBio Pharma in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of $4.31 for the year, down from their prior forecast of $4.38. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($2.59) per share.

Other equities research analysts also recently issued research reports about the company. Bank of America reiterated a "buy" rating and set a $42.00 price target on shares of BridgeBio Pharma in a report on Wednesday, September 11th. Evercore ISI lowered their target price on shares of BridgeBio Pharma from $50.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, August 7th. Piper Sandler initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, September 4th. They set an "overweight" rating and a $46.00 price target on the stock. Scotiabank assumed coverage on shares of BridgeBio Pharma in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $44.00 price objective for the company. Finally, Leerink Partners dropped their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of "Moderate Buy" and an average price target of $47.50.

BridgeBio Pharma Stock Down 2.7 %

BBIO stock traded down $0.68 during mid-day trading on Thursday, reaching $24.11. 1,913,282 shares of the company traded hands, compared to its average volume of 1,843,242. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of -10.00 and a beta of 1.09. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $44.32. The firm's 50 day moving average price is $25.78 and its 200 day moving average price is $26.44.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in BBIO. Profund Advisors LLC increased its holdings in shares of BridgeBio Pharma by 1.1% in the second quarter. Profund Advisors LLC now owns 51,029 shares of the company's stock worth $1,293,000 after purchasing an additional 555 shares during the period. American International Group Inc. increased its stake in BridgeBio Pharma by 1.0% in the 1st quarter. American International Group Inc. now owns 57,491 shares of the company's stock worth $1,778,000 after acquiring an additional 565 shares during the last quarter. Bfsg LLC raised its holdings in shares of BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company's stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock valued at $135,000 after acquiring an additional 801 shares during the last quarter. Finally, Amalgamated Bank grew its holdings in shares of BridgeBio Pharma by 24.7% during the second quarter. Amalgamated Bank now owns 4,863 shares of the company's stock worth $123,000 after purchasing an additional 962 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares of the company's stock, valued at $650,470,003.25. The trade was a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Brian C. Stephenson sold 4,155 shares of the firm's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $102,586.95. Following the completion of the transaction, the chief financial officer now directly owns 85,192 shares of the company's stock, valued at approximately $2,103,390.48. This trade represents a 4.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,831,544 shares of company stock valued at $150,128,821 over the last ninety days. 24.66% of the stock is currently owned by insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.